Merck (MRK) Announces Voluntary Nationwide Recall of CUBICIN 500mg, Due to Presence of Particulate Matter Identified as Glass Particles
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P, Dow edge higher on Mideast deal hopes; SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
CDC ACIP Unanimously Votes to Recommends Merck's (MRK) VAXNEUVANCE in Series with PNEUMOVAX as Option for Pneumococcal Vaccination in Appropriate Adults
October 21, 2021 5:43 AM EDTMerck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the U.S. Centers for Disease Control and Preventions (CDCs) Advisory Committee on Immunization Practices (ACIP) unanimously voted in favor of updates to pneumococcal vaccination recommendations for adults 65 years and older, and for adults ages 19 to 64 with certain underlying medical conditions (e.g., chronic conditions such as diabetes, chronic heart disease, chronic lung disease, or chronic liver disease, as well as HIV, an immunocompromising condition) or other disease risk factors (e.g., smoking, alcoholism). In both groups, the ACIP voted to... More
Merck (MRK) Strength Pre-Open Tied to Atea Pharmaceuticals Inc. (AVIR) Trial Missing Primary Endpoint
October 19, 2021 7:09 AM EDTMerck (NYSE: MRK) Strength Pre-Open Tied to Atea Pharmaceuticals Inc. (NASDAQ: AVIR) Trial Missing Primary Endpoint
Merck up 2.2%, Atea Still Halted... More
